Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 52-Week High - Here's Why

Key Points

• Aurinia Pharmaceuticals' stock reached a new 52-week high of $13.54 during trading, a notable increase in investor interest.
• Wall Street analysts have upgraded the stock's price targets, with HC Wainwright setting a target of **$17.00**, reflecting positive sentiment around the company's potential growth.
• Aurinia Pharmaceuticals reported quarterly earnings of **$0.16 EPS**, slightly below estimates, but revenue of **$70.01 million** exceeded expectations, indicating strong market performance.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP's stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $13.54 and last traded at $13.28, with a volume of 647183 shares traded. The stock had previously closed at $13.14.

Wall Street Analysts Forecast Growth

AUPH has been the subject of a number of research reports. Royal Bank Of Canada lifted their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $13.00.

Aurinia Pharmaceuticals Trading Down 16.0%

The company has a market cap of $1.45 billion, a price-to-earnings ratio of 25.63 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The firm's fifty day moving average price is $11.61 and its 200-day moving average price is $9.32.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The firm had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Activity

In other news, Director Kevin Tang purchased 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, August 1st. The stock was bought at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the acquisition, the director owned 11,029,500 shares in the company, valued at $111,618,540. The trade was a 9.97% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired a total of 1,300,000 shares of company stock worth $13,590,000 over the last three months. Insiders own 12.20% of the company's stock.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC lifted its holdings in Aurinia Pharmaceuticals by 57.3% in the second quarter. Corient Private Wealth LLC now owns 29,560 shares of the biotechnology company's stock worth $250,000 after purchasing an additional 10,768 shares during the period. Osaic Holdings Inc. lifted its holdings in Aurinia Pharmaceuticals by 43.9% in the second quarter. Osaic Holdings Inc. now owns 34,677 shares of the biotechnology company's stock worth $294,000 after purchasing an additional 10,585 shares during the period. Squarepoint Ops LLC lifted its holdings in Aurinia Pharmaceuticals by 195.4% in the second quarter. Squarepoint Ops LLC now owns 483,937 shares of the biotechnology company's stock worth $4,099,000 after purchasing an additional 320,124 shares during the period. Marex Group plc acquired a new stake in Aurinia Pharmaceuticals in the second quarter worth about $1,143,000. Finally, State of Wyoming acquired a new stake in Aurinia Pharmaceuticals in the second quarter worth about $240,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.